INTERIM RESULTS OF A PHASE 3b, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL EVALUATING 24-MONTH SAFETY OF ELAGOLIX WITH ADD-BACK FOR HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS

Authors
Category Primary study
JournalFertility and Sterility
Year 2022
This article has no abstract
Epistemonikos ID: 83cdaed1f06e0f89c444f860cf021ea341ab916e
First added on: Dec 20, 2022